T3 + T4 150mcg/tab 40 Tabletten by Sterling Knight Pharmaceuticals

Usage

1. Establish baseline: obtain fasting TSH, free T4, and free T3 serum values before starting — these reference points allow you to distinguish conversion efficiency from dosing adequacy during the cycle.
2. Take one tablet (or half-tablet during initiation) at the same time each morning, at least 30 minutes before food and away from calcium supplements or antacids, which reduce levothyroxine absorption by up to 40% per published pharmacokinetic data.
3. Compare your compound selection against your cycle goals: if you are running T4-only at 150 mcg rather than a T3/T4 blend, expect a 24–48 hour additional delay before peak metabolic output, and adjust caloric targets accordingly rather than escalating dose prematurely.
4. Use a pill cutter — not manual splitting — to bisect tablets for 75 mcg doses; Sterling Knight's GMP-compliant uniform tablet compression supports accurate halving, but only a dedicated cutting tool exploits that precision reliably.
5. Monitor resting heart rate and temperature weekly as proxy indicators of peripheral T3 availability; a sustained resting HR above 90 bpm or persistent fine tremor signals over-conversion and warrants a dose reduction step.
6. Plan the taper before starting: because the 6–7-day half-life creates a long hormone tail, begin step-down dosing at least two weeks before the intended protocol end date to avoid a prolonged suppression window on the HPT axis.

Warnings

Frequently asked questions

How does T4 Levothyroxine 150mcg compare to T3 Liothyronine in terms of potency and onset?

T4 is not directly comparable to T3 on a microgram-per-microgram basis because T4 must be converted to T3 by peripheral deiodination before exerting metabolic effects, whereas T3 acts immediately. This makes T3 faster-onset and shorter-acting, while T4 at 150 mcg produces a slower, more sustained elevation. Users prioritising hormonal stability typically choose T4; those needing rapid metabolic activation lean toward T3.

Which thyroid compound class — T3-only, T4-only, or a T3/T4 blend — is best suited for bodybuilding cut cycles?

T3-only products dominate short, aggressive cut protocols because direct triiodothyronine activity peaks faster and dose adjustments show quicker results. T4-only supplementation at 150 mcg is better suited to longer cycles where a steady metabolic baseline matters more than a rapid spike. T3/T4 blends offer a middle ground but reduce individual titration flexibility. The optimal choice depends on cycle length, sensitivity, and concurrent compounds.

Where do the side effect profiles of T4 and T3 differ most noticeably?

T3 carries a higher risk of acute cardiovascular effects — palpitations, tachycardia, and tremor — because active hormone levels rise quickly after each dose. T4 at 150 mcg distributes these effects over a longer time window via conversion, making symptom onset more gradual and easier to manage. However, cumulative over-dosing risk exists with both; the key difference is speed of onset, not ultimate severity at equivalent metabolic output.

Can Sterling Knight T4 150mcg tablets be split for lower-dose protocols?

The tablets are scored for physical splitting; a half-tablet delivers approximately 75 mcg, which aligns with standard initiation doses used before titrating to 100–150 mcg. For accurate splitting, use a pill cutter rather than manual pressure. Sterling Knight's GMP-certified tablet compression ensures uniform API distribution across the tablet, so halved doses reflect declared content rather than producing unpredictable API-rich or API-depleted fragments.

How many tablets are in one pack and how long does a 150mcg daily protocol last?

Each pack contains 40 tablets. At the full 150 mcg/day dose — one tablet daily — a single pack covers 40 days. At 75 mcg/day (half-tablet), the pack extends to 80 days. Because levothyroxine's 6–7-day half-life supports once-daily dosing, the blister format with individual push-through cavities makes it straightforward to track daily compliance without dividing or measuring doses beyond a single tablet or half-tablet. (2) angle_used

Manufacturer

Sterling Knight Pharmaceuticals' tablet release framework for its Levothyroxine 150 mcg/tab product is organised around a specific formulation risk that distinguishes this product from lower-concentration entries in the same thyroid line: at 150 mcg per tablet, the absolute API mass per unit is three times that of the companion 50 mcg T3 product, yet the tolerance band governing acceptable potency deviation does not scale proportionally — regulatorily, a tighter percentage deviation is expected as declared dose rises, because a 5% error on 150 mcg represents a materially larger absolute microgram swing than 5% on 50 mcg. Sterling Knight addresses this by applying a validated direct-compression or equivalent process that is calibrated specifically to the 150 mcg levothyroxine sodium load, with excipient selection chosen to minimise API migration within the tablet matrix during storage. Finished-tablet lots are tested by reverse-phase HPLC before release, confirming that the declared 150 mcg is present within the acceptable uniformity window across a representative tablet sample drawn from each production batch. This lot-specific verification — rather than reliance on API certificate data alone — is the quality control step that underpins the compound-comparison claim central to this product's positioning: when users are selecting between T4, T3, and blended preparations based on a specific microgram load, the declared figure must be analytically confirmed rather than assumed.